國家衛生研究院 NHRI:Item 3990099045/13837
English  |  正體中文  |  简体中文  |  全文笔数/总笔数 : 12145/12927 (94%)
造访人次 : 855441      在线人数 : 1111
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜寻范围 查询小技巧：
  • 您可在西文检索词汇前后加上"双引号"，以获取较精准的检索结果
  • 若欲以作者姓名搜寻，建议至进阶搜寻限定作者字段，可获得较完整数据
    •  进阶搜寻
    主页 ‧ 登入 ‧ 上传 ‧ 说明 ‧ 关于NHRI ‧ 管理 到手机版


    jsp.display-item.identifier=請使用永久網址來引用或連結此文件: http://ir.nhri.org.tw/handle/3990099045/13837


    题名: Network meta-analysis and trial sequential analysis for atrial fibrillation patients receiving PCI or with ACS
    作者: Yang, SM;Huang, CJ;Chen, CH;Yu, WC;Sung, SH;Guo, CY;Chuang, SY;Cheng, HM;Chiang, CE
    贡献者: Institute of Population Health Sciences
    摘要: BACKGROUND: In patients with atrial fibrillation (AF) and acute coronary syndrome (ACS) or undergoing percutaneous coronary intervention (PCI), choosing the most appropriate antithrombotic treatment remains a dilemma. We aimed to compare the relative efficacy and safety outcomes of antithrombotic drugs in patients with AF after undergoing PCI or ACS. METHODS: Randomized controlled trials were systematically searched on PubMed, EMBASE, and the Cochrane Library. Five studies (11,532 patients) were included in the network meta-analysis (NMA). Trial sequential analysis (TSA) was performed to assess the reliability and conclusiveness of the meta-analysis comparing the dual antithrombotic therapy strategies with the triple antithrombotic therapy strategy. RESULTS: Compared with vitamin K antagonist (VKA) + dual antiplatelet therapy (DAPT), novel oral anticoagulant (NOAC) + P2Y12 inhibitor was associated with a significantly better trial-defined primary safety outcome (odds ratio: 0.53; 95% CI: 0.31 - 0.90) and the lowest probability of thrombolysis in myocardial infarction (TIMI) major bleeding and intracranial hemorrhage using the cumulative ranking technique. In patients omitting aspirin, TSA demonstrated conclusive evidence with significant decreases in all safety outcomes and inconclusive evidence with a non-significant increase in in-stent thrombosis (risk ratio: 1.32; TSA-adjusted 95% CI: 0.54 - 3.24) and myocardial infarction (risk ratio: 1.19; TSA-adjusted 95% CI: 0.84 - 1.68). CONCLUSION: In patients with AF receiving PCI or with ACS, NOAC + P2Y12 inhibitor was associated with the lowest bleeding risk but resulted in a statistically non-significant, numerically greater risk for stent thrombosis and myocardial infarction, suggesting that triple antithrombotic therapy (TAT) should still be an option for certain patients at a high risk of stent thrombosis or myocardial infarction.
    日期: 2022-01-01
    關聯: Journal of the Chinese Medical Association. 2022 Jan 1;85(1):59-66.
    Link to: http://dx.doi.org/10.1097/jcma.0000000000000651
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=1726-4901&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000838769100009
    Cited Times(Scopus): https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85123457260
    显示于类别:[莊紹源] 期刊論文

    文件中的档案:

    档案 描述 大小格式浏览次数
    PUB34759208.pdf1830KbAdobe PDF188检视/开启


    在NHRI中所有的数据项都受到原著作权保护.

    TAIR相关文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回馈